cations for high-dose therapy are increasing, its execution will probably need to be more and more extended to smaller hospitals.
germ-free diet. In the event of fever a combination of Stem cell rescue broad-spectrum antibiotics was given. Hemoglobin was Until the end of 1992 we rescued patients with autologous maintained above 8 g/dl and platelets above 5 × 10 9 /l (or bone marrow. The median number of bone marrow cells 10 × 10 9 /l in case of infection) by transfusing irradiated reinfused was 4.4 × 10 7 MNC/kg (range 1-15.4). Since blood products.
1993 all transplants have been performed with blood stem Data from the medical and nurses' records of all patients cells alone. In that year we began administering multiple treated in our department from July 1989 until July 1995 stem cell rescues after sequential high-dose therapy for teswith high-dose therapy and stem cell rescue were collected ticular cancer, breast cancer and lymphoma. retrospectively. To analyze the data we used descriptive
The median number of cells collected by leukapheresis statistics as well as Kaplan-Meier curves produced by the and reinfused was 6.9 × 10 8 MNC/kg (range 2.19-17.71), product limit method for overall and disease-free survival.
4.1 × 10 6 CD34 + /Kg (range 1.0-26.7) and 46 × 10 4 GMThe Rothmann's method was used for estimation of the CFC/kg (range 6-115). A fairly good correlation was found confidence limits. Definitions of the clinical end-points are between CD34 + and the GM-CFC counts (r = 0.54). those of the WHO for reporting cancer clinical trials.
8,9
Aplasia and engraftment
The supportive care needs are summarized in Figure 1 Results according to the type of rescue. Patients who had received a treatment believed to be either myeloablative or just myePatient characteristics losuppressive are described separately (BSC transplantation vs BSC support, respectively). Patients transplanted with Of the 40 transplanted patients 19 were males and 21 autologous bone marrow recovered from neutropenia a females, and their median age was 39 (range . median of 33.5 days after stem cell reinfusion. Only two Twenty-seven patients (70%) had hematologic maligof them had received growth factors after transplantation. nancies, 20 of which were lymphomas. The details of these A dramatic decrease in time to neutrophil recovery was malignancies are listed in Table 1 . Most of the patients seen with the advent of blood stem cells: median 12 days were screened for the presence of tumor cells in the bone without and 9 days with the association of growth factors. marrow at diagnosis (13 positive) and again at the beginThe time to platelet recovery dropped from a median of 40 ning of the conditioning regimen (four positive).
days with ABMT to a median of 6 days with BSCT and the number of days in hospital from 43 days to 20 days, the number of days with i.v. antibiotics from 14 to 4 days, High-dose therapy the number of transfused red cell units from 10 to 2 units per patient. The number of transfused platelet aphereses Depending on diagnosis and physician's preference, patients were conditioned with the BEAM regimen 10 (four was reduced from 15 to two per patient. The use or omission of growth factors had no influence on these parapatients), TBI and melphalan 11 (four patients), mitoxantrone and melphalan 12 (nine patients), busulfan-cyclophosmeters. Patients receiving BSC just as a rescue to shorten the time of aplasia (BSC support) had even lower supportphamide 13 (four patients), epirubicine and cyclophosphamide (four patients) or combinations containing high-doses ive care needs: 15 days of hospitalization, 5 days on i.v. antibiotics and no platelet transfusions. None of the patients of carboplatin, cyclophosphamide, melphalan or etoposide. None of these patients was treated as part of a multicensuffered from septic shock or life-threatening hemorrhage. All patients engrafted permanently. In those transplanted ter trial. 
Discussion
The main objective of this report is to demonstrate the feasibility of high-dose therapy in non-university hospitals.
As expected, the change of stem cell source from bone marrow to blood cells produced an impressive reduction in time spent in isolation and in hospital, days with parenteral antibiotics and number of platelets and red cell units transfused, rendering this treatment even simpler for our peripheral hospitals. None of our patients died as a consequence of the myelosuppressive regimen and no serious or life-threatening events leading to permanent sequelae have been recorded. In fact, as far as the management of patients in aplasia is concerned, this is now not very different from that of a patient with acute leukemia, so that any clinical ward treat- nected with obtaining and processing stem cells. For this, a special laboratory with trained personnel is necessary, which must at least be able to perform cryopreservation, with BSC, no relationship was found between the number of CD34
+ or GM-CFC reinfused and time to engraftment, and if possible CD34 + counts and clonogenic assays to estimate the number of GM-CFC. The reasonable correlation possibly because all engraftments occurred in a short time (maximum 15 days for neutrophils and 10 days for which we found between the number of CD34 + and GM-CFC demonstrates that the results from our laboratory are platelets).
reliable. The other indispensable condition is perfect cooperation with a blood bank which can provide platelets at Non-hematologic toxicities any time when necessary. However, to be applicable to more small centers, highSome adverse effects not due to aplasia were seen. One patient developed a transient hemiparesis following hypodose therapy must become even simpler and cheaper than it is now. This may be possible with more efficient mobiliztension just after the reinfusion of blood stem cells. This episode was believed to have been due to DMSO.
14 A ation schemes, less toxic conditioning regimens and simpler isolation procedures. chronic hepatitis B infection was reactivated causing transient hepatic failure, which resolved after treatment with
The best mobilizer is currently G-CSF, 15,16 with or without chemotherapy, but better mobilization techniques need prednisone and gancyclovir. A transient cardiomyopathy with slight asymptomatic cardiac insufficiency was seen in to be developed. Using continuous flow instead of intermittent flow cell separators and/or mobilizing previously a patient with lymphoma in first relapse previously treated with 200 mg (total dose) of doxorubicin and mediastinal untreated patients allows the collection of enough cells in just one session of leukapheresis, resulting in less time and radiotherapy with 45 Gy after conditioning with the BEAM regimen. One patient treated for lymphoma died a year after resources used for cells collection.
17
Fewer complications associated with conditioning will transplant of a disseminated herpes virus, possibly secondary to the transplant-related immunosuppression.
also reduce morbidity and costs. Although we have seen none in our center, toxicities associated with TBI, busulfan or BCNU, given at high doses, are commonly described in Disease progression and survival the literature. 18 None of the lung, heart or liver complications associated with these treatments are reported with The median follow-up of the entire group is 2 years. The 20 patients with lymphoma were analyzed as a single group a regimen such as the high-dose sequential chemotherapy described by Gianni et al 12 and this was a main reason for and show a 48% probability of progression-free survival beyond 2 years (95% confidence interval 28-68%) (Figure our deciding to adopt this combination to treat patients with Hodgkin's and non-Hodgkin's lymphoma. 2). Their probability of survival at 2 years is 68% (95% confidence interval 46-84%) (Figure 3) . Of the six patients
To simplify further the procedure, high-dose treatment can be administered as an out-patient regimen, with patients with acute leukemia, only one is progression free after more spending their time in aplasia at home and coming to the with lymphoma and acute myelogenous leukemia without a sibling or unrelated compatible donor. Currently, having hospital every other day for blood counts, clinical examination, and to receive red cells or platelet units if necessary.
observed that about half of the high-risk patients with lymphoma can achieve long-term remission with high-dose Several centers are now introducing this practice, with satisfactory results. 19 therapy, we are encouraged to continue transplanting patients with lymphoma in relapse. We also joined a multiOur patients with lymphoma demonstrate an encouraging progression-free survival (48%) and overall survival (68%).
center randomized trial of high-dose chemotherapy vs standard treatment for patients with high-grade high-risk NHL These results are comparable to those of larger centers who have treated patients with similar characteristics: in Seattle, at first presentation. Conversely, given the deceiving results in our patients and the controversial data in the literature, 53 patients with lymphoma (Hodgkin's, high-grade and low-grade non-Hodgkin's), the majority of whom were in we abandoned the indication of acute leukemia and solid tumors outside of randomized trials. For AML and breast relapse, showed a DFS of 43% 2 years after transplantation and an overall survival of 54%. 20 An equivalent group of cancer we adhered to multicenter randomized trials.
In conclusion, we demonstrate that high-dose chemo-96 patients transplanted at Stanford achieved, at 3 years, a DFS of 55-60% and a survival of 55%. 21 therapy with autologous stem cell rescue has become easy enough to be performed in a peripheral hospital, provided Up to now, our patient selection has been influenced by the policies of the insurance companies, which in Switzerit is equipped with the necessary technical, personnel and blood bank facilities. Our results in terms of both feasibility land have agreed to pay for this procedure only for patients insurance companies, will need to be addressed.
11 Carey PJ, Proctor SJ, Taylor P et al. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. Blood 1991; 77: 1593-1598.
